89283-32-9

Usage

Uses

Used in Pharmaceutical Industry:
(3-Chloropyrazin-2-yl)methanol is used as a synthetic intermediate for the preparation of indazolylquinazolinones, which are potent inhibitors of human immunodeficiency virus (HIV) replication. These compounds have the potential to be developed into effective antiretroviral drugs, offering new treatment options for HIV-infected individuals.
Additionally, (3-chloropyrazin-2-yl)methanol can be utilized in the synthesis of other bioactive molecules and pharmaceutical agents, given its unique structural features and reactivity. Its applications in drug discovery and development are promising, as it can contribute to the creation of novel therapeutic agents with improved efficacy and selectivity.

InChI:InChI=1/C5H5ClN2O/c6-5-4(3-9)7-1-2-8-5/h1-2,9H,3H2

Upstream product

• 121246-96-6 3-chloro-2-pyrazinecarboxaldehyde 
• 14508-49-7 2-chloropyrazin 
• 68-12-2 N,N-dimethyl-formamide 
• 79-22-1 methyl chloroformate 
• 27398-39-6 3-chloropyrazine-2-carboxylic acid 

Downstream Products

• 45660-95-5 2-chloro-3-(chloromethyl)pyrazine 
• 867165-55-7 2-((3-chloropyrazin-2-yl)methyl)isoindoline-1,3-dione 
• 771581-15-8 (3-chloro-pyrazin-2-yl)-methylamine 
• 1320266-92-9 8-chloro-1-iodo-3-isopropylimidazo[1,5-a]pyrazine 
• 1320266-94-1 1-iodo-3-isopropylimidazo[1,5-a]pyrazin-8-amine 
• 1320266-96-3 C₁₀H₁₄ClN₃O 
• 1320266-90-7 8-chloro-3-isopropylimidazo[1,5-a]pyrazine 

Relevant academic research and scientific papers

Preparation of HIF-2alpha small-molecule inhibitor and application thereof

The invention belongs to the technical field of medicines, and relates to an HIF-2 alpha small-molecule inhibitor as well as a preparation method and an application thereof. The HIF-2alpha small-molecule inhibitor is a compound as shown in a structural general formula I and a stereoisomer, a pharmaceutically acceptable salt, a hydrate, a solvate or a prodrug thereof. According to the invention, molecular simulation drug design software MOE is used for screening and molecular docking of pharmacophores, according to a final docking dominant structure and an isosteric principle, a series of compounds are designed and synthesized, and an in-vitro anti-tumor activity screening test shows that the compounds have anti-tumor activity. The HIF-2 alpha small-molecule inhibitor provided by the invention has a relatively good application prospect in the aspect of preventing or treating cancers, particularly glioma.

Compound used as Bruton tyrosine kinase inhibitor, and preparation method and application of compound

The invention provides a compound with a structure shown as the formula (I), or an isomer, pharmaceutically acceptable solvate and salt thereof, which is used as the Bruton tyrosine kinase inhibitor. The Bruton tyrosine kinase inhibitor has higher inhibit

ALDEHYDE COMPOUNDS FOR TREATING PULMONARY FIBROSIS, HYPOXIA, AND CONNECTIVE TISSUE AND AUTOIMMUNE DISEASE

This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.

SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone deriva

SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.